Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MicroRNA-based early hepatic fibrosis diagnosis marker and kit

A diagnostic kit and diagnostic marker technology, applied in the direction of microbial determination/examination, biochemical equipment and methods, etc., can solve the problem of difficult to describe markers specific to liver fibrosis, few research samples, and inability to be comprehensive and objective. Reflecting problems such as circulating microRNA, saving time and labor costs, and avoiding complicated detection

Pending Publication Date: 2021-06-08
诸暨瑞健生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Aiming at the deficiencies of the prior art, the present invention provides a microRNA-based early liver fibrosis diagnostic marker and kit, aiming to solve the situation that the circulating microRNA may not be fully and objectively reflected, some research samples are few, and it is difficult to explain the definite marker Specific diagnostic markers for early liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MicroRNA-based early hepatic fibrosis diagnosis marker and kit
  • MicroRNA-based early hepatic fibrosis diagnosis marker and kit
  • MicroRNA-based early hepatic fibrosis diagnosis marker and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] In Figure 1, 11 miRNAs were selected as candidate miRNAs, which were differentially expressed in plasma of patients with SPNALT, including miR-130-3P, miR-140-3P, miR-151A-3P, MIR-320A, MIR-320B, MIR- 361, MIR-423-5P and MiR-320a were low expression in plasma in patients with spnalt, while MiR-122-5P, miR-7975, miR-7977 was highly expressed, and the 11 miRNAs were preliminary in TAQMAN probe QPCR. Verification, the results showed that four miRNAs were differentially expressed in plasma of patients with spnalt, namely MiR-122-5P, MIR-151A-3P, MIR-140-3P and MIR-320B, compared to NpnAlt and health group, MIR-122 The plasma expression levels in the -5P and miR-151A-3P were significantly rising and decreased (P value: P = 0.027 <0.05, P = 0.002 <0.05; P = 0.028 <0.05, p = 0.000 <0.01 The result of the previous chip screening is consistent; however, the plasma expression levels of miR-140-3P and miR-30D increased significantly in the spnalt group (P = 0.014 <0.05, p = 0.026; <0....

Embodiment 2

[0056] Table 1. Basic Characteristics of MiRNAs in this application

[0057] Mirnas Name Foldchange PVALUE Up-regulate MIR-122-5P 15.60390762 0.014086604 MIR-7975 2.385684592 0.012760626 MIR-7977 2.765338185 0.024320926 MIR-1260A 2.086515206 0.010217115 MIR-6125 3.002375671 0.032804494 Down-Regaluted MIR-130B-3P 0.48506793 0.035250824 MIR-140-3P 0.48826817 0.029497252 MIR-151A-3P 0.38595192 0.006746703 MIR-320A 0.422711253 0.017810562 MIR-320D 0.287118213 0.031172524 MIR-361-5P 0.474121976 0.013009276 MIR-423-5P 0.362739062 0.012701571 MIR-486-5P 0.456280672 0.028838438 MIR-320B 0.338475206 0.022090953 MIR-320E 0.261952637 0.038086723 MIR-324-3P 0.428690312 0.006556401 MIR-484 0.484917882 0.006419125 MIR-6127 0.481246124 0.038785289

[0058] The miRNAS chip was used to analyze miRNAs between the whole genomic difference betwe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a microRNA-based early hepatic fibrosis diagnosis marker and a kit. The microRNA-based early hepatic fibrosis diagnosis marker comprises nucleic acid molecules encoding the combination of the following microRNA molecules: Has-miR-122 and Has-miR-151-3p. Furthermore, the level of the microRNA in the plasma of a PNALT patient with hepatic fibrosis is higher than level of the microRNA in the plasma of a healthy person and the level of the microRNA in the plasma of a PNALT patient without hepatic fibrosis. Furthermore, the obtaining method of the PNALT hepatic fibrosis diagnosis combination composed of the plasma microRNA comprises the following steps: step 1, high-throughput sequencing; step 2, carrying out real-time quantitative fluorescent PCR verification; step 3, determining a plasma microRNA combination capable of distinguishing hepatic fibrosis and non-fibrosis in a training group consisting of healthy people, PNALT patients without hepatic fibrosis and PNALT patients with hepatic fibrosis; and step 4, verifying the liver fibrosis diagnosis effect of the plasma microRNA combination established in the step 3 in the two independent verification groups. The condition of circulating microRNA is comprehensively and objectively reflected, multi-center verification is added, the perfection degree of contrast setting is improved, and it can be conveniently indicated that the determined marker is a specific diagnosis marker for early hepatic fibrosis.

Description

Technical field [0001] The present invention relates to the field of biological detection, and in particular, to a microRNA-based early liver fibrosis diagnostic marker and kit. Background technique [0002] There are approximately 3.5-4 billion people in the world for Hepatitis B Virus (HBV) infected, and Chinese patients with chronic hepatitis B Virus (CHB) have reached 120 million, HBV-related liver disease. The pathogenesis is generally present: "HBV continuous infection → hepatic fibrosis → cirrhosis → liver cell liver carcinoma", wherein the liver fibrosis is the only reversible stage. Effective antiviral treatment can delay liver hardness and liver cancer. The reversal of fibrosis is therefore critical to the intervention of CHB infection to intervene in different stages of liver fibrosis. It is an urgent health problem that needs to be solved. [0003] Hepatic fibrosis is a pathophysiological process refers to abnormal hyperplasia from intrahemmonic tissue caused by vario...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 程锦霖
Owner 诸暨瑞健生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com